Drug Profile
Botulinum toxin A - AbbVie/Medytox
Alternative Names: ABBV-950; Botulift; Botulinum toxin type A; Cunox; Innotox; KbtxA; Liquid-type botulinum toxin type A - AbbVie; MBA-P01; Meditoxin; MT 10107; MT 10109; MT10109L; Neuronox; NivobotulinumtoxinA; SiaxLatest Information Update: 01 Feb 2024
Price :
$50
*
At a glance
- Originator Medy-Tox
- Developer AbbVie; Medytox
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Blepharospasm; Equinus foot deformity; Glabellar lines; Muscle spasticity; Spasm
- Phase III Facial wrinkles; Hyperhidrosis; Overactive bladder; Torticollis
- No development reported Hypertrophy